Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities

Journal of the National Cancer Institute

Volumn 98, Issue 13, 2006, Pages 932-936

  Dings, Ruud P M ^a   Chen, Xuemei ^b   Hellebrekers, Debby M E I ^c   van Eijk, Loes I ^c   Zhang, Ying ^a   Hoye, Thomas R ^b   Griffioen, Arjan W ^c   Mayo, Kevin H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of Minnesota   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

0118; 1097; ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOSTATIC PROTEIN; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA SHEET; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENDOTHELIUM CELL; HYDROPHOBICITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DRUG DESIGN; FEASIBILITY STUDIES; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; OVARIAN NEOPLASMS; PROTEINS;

EID: 33745776265     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj247     Document Type: Article

References (30)

1. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
2. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
3. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
5. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol 2000;19:597-614.
6. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis 2003;6:83-91.
7. Dings RP, Arroyo MM, Lockwood NA, Van Eijk LI, Haseman JR, Griffioen AW, et al. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J 2003;23:281-8.
8. Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, et al. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem 2003;278:45746-52.
9. Gutsche CD, Bauer LJ. Calixarenes. 13. The conformational properties of calix[4]arenes, calix[6]arenes, calix[8]arenes, and oxacalixarenes. J Am Chem Soc 1985:107:6052-9.
10. Gutsche CD, Dhawan B, Levine JA, No KH, Bauer LJ. Calixarenes. 9. Conformational isomers of the ethers and esters of calix[4]arenes. Tetrahedron 1983;39:406-26.
11. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 2002; 16:1991-3.
12. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001; 354:233-42.
13. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003;63: 382-5.
14. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 2003;194:55-66.
15. Pinheiro JC, Bates DM. Mixed-effects models in S and S-plus. 1st ed. New York (NY): Springer-Verlag; 2000. p. 528
16. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: Effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59:368-76.
17. Fairlie DP, West ML, Wong AK. Towards protein surface mimetics. Curr Med Chem 1998;5:29-62.
18. Yin H, Hamilton AD. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. Bioorg Med Chem Lett 2004;14:1375-9.
19. Yin H, Lee GI, Sedey KA, Rodriguez JM, Wang HG, Sebti SM, et al. Terephthalamide derivatives as mimetics of helical peptides: Disruption of the Bcl-x(L)/Bak interaction. J Am Chem Soc 2005;127:5463-8.
20. Kelso MJ, Beyer RL, Hoang HN, Lakdawala AS, Snyder JP, Oliver WV, et al. Alpha-turn mimetics: Short peptide alpha-helices composed of cyclic metallopentapeptide modules. J Am Chem Soc 2004;126:4828-42.
21. Loughlin WA, Tyndall JD, Glenn MP, Fairlie DP. Beta-strand mimetics. Chem Rev 2004; 104:6085-117.
22. Schneider JP, Kelly JW. Templates that induce alpha-helical, beta-sheet, and loop conformations. Chem Rev 1995;95:2169-87.
23. Nowick JS, Pairish M, Lee IQ, Holmes DL, Ziller JW. An extended beta-strand mimic for a larger artificial beta-sheet. J Am Chem Soc 1997;119:5413-24.
24. Eguchi M, Kahn M. Design, synthesis, and application of peptide secondary structure mimetics. Mini Rev Med Chem 2002;2:447-62.
25. Kee KS, Jois SD. Design of beta-turn based therapeutic agents. Curr Pharm Des 2003;9:1209-24.
26. Perkins JJ, Duong LT, Femandez-Metzler C, Hartman GD, Kimmel DB, Leu CT, et al. Non-peptide alpha(v)beta(3) antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. Bioorg Med Chem Lett 2003; 13:4285-8.
27. Sheppard GS, Kawai M, Craig RA, Davidson DJ, Majest SM, Bell RL, et al. Lysyl 4-aminobenzoic acid derivatives as potent small molecule mimetics of plasminogen kringle 5. Bioorg Med Chem Lett 2004;14:965-6.
28. Hasegawa A, Cheng X, Kajino K, Berezov A, Murata K, Nakayama T, et al. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A 2004;101:6599-604.
29. Alexopoulos K, Fatseas P, Melissari E, Vlahakos D, Roumelioti P, Mavromoustakos T, et al. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: Platelet aggregation and relaxant activities. J Med Chem 2004;47:3338-52.
30. Xuereb H, Maletic M, Pelczer I, Gildersleeve J, Kahne D. Design of an oligosaccharide scaffold that binds in the minor groove of DNA. J Am Chem Soc 2000;122:1883-90.